Biovitrum wins contract to manufacture pharmaceutical substance for Resistentia's clinical phase III trials
clinical phase III trials of new protein-based drug candidate for the treatment of allergy
10-Nov-2006 -
Biovitrum has entered an agreement with the Uppsala-based biotech company Resistentia Pharmaceuticals AB for process development and manufacturing of the biopharmaceutical substance RES 08 intended for use in clinical phase III trials of Resistentia's new protein-based drug candidate for the ...
allergic reactions
allergies
Biovitrum
+4